Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and ...
Recursion Pharmaceuticals recently announced a licensing agreement to integrate HealthVerity's extensive real-world data into its platforms. In the same week, Recursion reported significant ...
PHILADELPHIA - Recursion (NASDAQ: RXRX), a clinical stage TechBio company with a market capitalization of $2.27 billion, has entered into a licensing agreement with HealthVerity to utilize its ...
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...
NVIDIA-BACKED Recursion Pharmaceuticals said on Tuesday (Sep 3) its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results